Industries
mRNA Therapeutics
mRNA therapeutics harness synthetic messenger RNA to encode proteins from vaccine antigens to intracellular enzymes, enabling rapid development cycles and personalized dosing. Lipid nanoparticle delivery chemistry, cap analogue chemistry, and nucleoside modification are the key academic IP generators the industry actively licenses.
Details
- Companies
- ModernaBioNTechArctus BiotherapeuticsCureVacTranslate Bio SanofiEthrisLarimar TherapeuticsProQR TherapeuticsStrand TherapeuticsOmniVax
- Market Size
- $24B
- Target Researchers
- RNA biologists, biochemists, and drug delivery scientists with expertise in mRNA sequence optimization, 5-prime cap analogues, lipid nanoparticle formulation, innate immune evasion, and manufacturing of nucleic acid therapeutics
- Use Cases
- LNP formulation licensingmRNA sequence optimization consultingRNA modification technology transferCold-chain logistics partnershipsAnalytical characterization servicesGMP RNA synthesis outsourcing